JS005 (recombinant humanized monoclonal antibody against IL-17A)

BIOLOGICAL3 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Moderate to Severe Chronic Plaque PsoriasisModerate to Severe PsoriasisTolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

Phase 1

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

CompletedNCT04220073

Shanghai Junshi Bioscience Co., Ltd.Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

Start: 2020-05-17End: 2020-11-20Updated: 2026-08-13

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

CompletedNCT05344248

Shanghai Junshi Bioscience Co., Ltd.Moderate to Severe Psoriasis

Start: 2021-01-20End: 2022-11-01Updated: 2022-12-08

Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT05975268

Shanghai Junshi Bioscience Co., Ltd.Moderate to Severe Chronic Plaque Psoriasis

Start: 2023-08-28End: 2025-09-03Updated: 2025-12-16